



**Silence Therapeutics plc (“Silence” or the “Company”)**

**Senior Independent Director**

**London 12 February 2010** – The Board of Silence (AIM: SLN) is pleased to announce that Mr Jerry Randall, an existing Non-Executive Director of the Company, has been appointed the Senior Independent Director in accordance with the recommendations of the Combined Code on Corporate Governance.

Mr Randall will be available to shareholders if they have a concern they wish to raise and where contact with the Chairman or Chief Executive would be inappropriate or where such contact has failed to resolve the concern.

- Ends -

**Silence Therapeutics plc**

+44(0)20 7491 6520  
Phil Haworth, CEO  
Melvyn Davies, Finance Director

**Vida Communications**

+1 415 675 7400  
Tim Brons (media)  
Stephanie Diaz (investors)

**Senior Independent Director**

Jerry Randall  
+44(0)20 7491 6520  
j.randall@silence-therapeutics.com

**Nominated Advisers**

**Nomura Code Securities Limited**  
+44(0)20 7776 1200  
Richard Potts  
Chris Collins

Notes to Editors:

**About Silence Therapeutics plc ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))**

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Through the merger with Intradigm, the group has a second, complementary delivery technology offering safe and effective systemic administration using a library of novel peptide-based biodegradable polycationic polymers.

Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence’s unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in clinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. In June 2009, the company initiated an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (malignant) tumors involving single, as well as, repeated intravenous administration.

Silence is one of only two companies worldwide with a proprietary position on composition of matter for siRNA therapeutics. In addition, through the merger with Intradigm the group has an impressive proprietary portfolio of siRNA sequences against more than 50 highly valued oncology and other disease targets and has secured an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is based in London, Berlin and Palo Alto, CA, and is listed on AIM.

### **Forward-Looking Statements**

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

